Curadh is pioneering the eradication of solid tumors through the new science of molecularly targeted radiation
About us
Patients, their families and loved ones are waiting for skilled researchers to cure cancer.
CuradhMTR has a highly experienced team focused on the new field of molecularly targeted radiation (MTR), with experts in all stages of oncology drug development and a track record of successful MTR development.
Explore our latest news and insights
Curadh MTR debuts at BioEquity, Europe with New CEO and Expanded Leadership Team
Curadh MTR Inc., leading the development of 2nd generation radiopharmaceuticals, designed to eradicate solid tumours, today announced its emergence from stealth with the appointment of Glenn Kazo as Chief Executive Officer and Amrik Basran as Chief Scientific Officer.
Northstar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors
NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. (Curadh), a global MTR-focused clinical, research and advisory organization, today announced a long-term strategic collaboration to develop and produce novel radiopharmaceuticals for the diagnosis and treatment of solid tumor cancers.
Shine Technologies and Curadh MTR Announce Expanded Strategic Partnership to Advance Cancer Therapies using Terbium and Lutetium
The strategic collaboration between Curadh MTR Inc. and SHINE Technologies marks a pivotal moment in the advancement of cancer therapies. This alliance promises to harness the potential of radioisotopes using Terbium and Lutetium to target and eliminate cancer cells with precision, offering renewed hope to patients and reshaping the future of cancer treatment.